Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Autor: Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)

Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS

Externí odkaz: https://doaj.org/article/193c505adea04fdda590997c6e7e69c0

Supplementary Data from Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial

Autor: Stephanie E. Combs, Andreas Sauter, Michal Devecka, Bernhard Haller, Hanno Specht, Michael Molls, Thomas Duell, Hubert Hautmann, Rudolf Huber, Dorota Lubgan, Rainer Fietkau, Claus Rödel, Matthias Hautmann, Konrad Kokowski, Norbert Ahrens, Robert Offner, Martin Hildebrandt, Christiane Blankenstein, A. Graham Pockley, Caroline Werner, Maxim Shevtsov, Wolfgang Sievert, Stefan Stangl, Sophie Seier, Gabriele Multhoff

Supplemetary Tables 1-3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6096135ebff975e56abb115589775700
https://doi.org/10.1158/1078-0432.22476339.v1

Membrane Hsp70—A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition

Autor: Stephanie Breuninger, Stefan Stangl, Caroline Werner, Wolfgang Sievert, Dominik Lobinger, Gemma A. Foulds, Sarah Wagner, Anja Pickhard, Guido Piontek, Konrad Kokowski, Alan G. Pockley, Gabriele Multhoff

Publikováno v: Frontiers in Oncology, Vol 8 (2018)

The presence of circulating tumor cells (CTCs) in the peripheral blood is a pre-requisite for progression, invasion, and metastatic spread of cancer. Consequently, the enumeration and molecular characterization of CTCs from the peripheral blood of pa

Externí odkaz: https://doaj.org/article/30cc236dfaa4406ba6f62e2690c17151

Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study

Autor: Martin Hildebrandt, Peter Vaupel, Gabriele Multhoff, Stefan Stangl, Sophie Seier, Konrad Kokowski

Publikováno v: Strahlenther. Onkol. 195, 352-361 (2019)
Strahlentherapie Und Onkologie

Background Membrane heat shock protein 70 (mHsp70) is indicative of high-risk tumors and serves as a tumor-specific target for natural killer (NK) cells stimulated with Hsp70 peptide (TKD) and Interleukin(IL)-2. Radiochemotherapy (RCT), mHsp70-target

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c356b284e11aac31df420685ecb116d
https://doi.org/10.1007/s00066-019-01434-9

Afatinib as first-line treatment in patients with

Autor: Wolfgang M, Brückl, Martin, Reck, Frank, Griesinger, Harald, Schäfer, Cornelius, Kortsik, Tobias, Gaska, Justyna, Rawluk, Stefan, Krüger, Konrad, Kokowski, Stephan, Budweiser, Joachim H, Ficker, Christopher, Hoffmann, Andrea, Schüler, Eckart, Laack

Publikováno v: Therapeutic advances in medical oncology. 13

Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::25bcff10ca780651c68152227b87cdbb
https://pubmed.ncbi.nlm.nih.gov/33995597